Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Total Non-Current Liabilities (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $361.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities rose 3.06% year-over-year to $361.4 million, compared with a TTM value of $361.4 million through Dec 2025, up 3.06%, and an annual FY2025 reading of $361.4 million, up 3.06% over the prior year.
  • Total Non-Current Liabilities was $361.4 million for Q4 2025 at Xeris Biopharma Holdings, down from $367.7 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $367.7 million in Q3 2025 and bottomed at $131.8 million in Q3 2021.
  • Average Total Non-Current Liabilities over 5 years is $296.8 million, with a median of $323.4 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities soared 65.28% in 2022, then rose 0.28% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $186.6 million in 2021, then soared by 46.65% to $273.6 million in 2022, then rose by 19.86% to $328.0 million in 2023, then grew by 6.92% to $350.7 million in 2024, then increased by 3.06% to $361.4 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for XERS at $361.4 million in Q4 2025, $367.7 million in Q3 2025, and $346.2 million in Q2 2025.